Pancragen (KEDW) — Research Peptide Bulk Supply
Also known as: Lys-Glu-Asp-Trp, KEDW tetrapeptide, Pancreatic bioregulator peptide
Pancragen (Lys-Glu-Asp-Trp) is a Khavinson tetrapeptide bioregulator studied for pancreatic cell differentiation and glucose metabolism research.
Khavinson short-peptide bioregulators are listed for catalog and chromatin / gene-expression research framing only. PeptideDistro.com makes no clinical, dosage, or treatment claims.
Bulk Catalog Specifications
- Lyophilized powder
- Purity: >99% by HPLC
- Available research vial sizes: 10 mg, 20 mg
- Storage: -20°C, protect from light
- Solubility: Soluble in sterile water
- COA with HPLC and mass spectrometry data provided per lot
- Cold-chain shipping documentation available
- Private-label and white-label bulk inquiry form available
Scientific Identifiers
| Sequence | Lys-Glu-Asp-Trp (KEDW tetrapeptide) |
|---|---|
| Residue count | 4 |
| Molecular formula | TBD |
| Molecular weight | TBD |
Research Mechanism Summary
Pancragen (Lys-Glu-Asp-Trp, KEDW) is a synthetic tetrapeptide bioregulator derived from bovine pancreatic tissue, developed by Khavinson et al. The peptide penetrates cell and nuclear membranes to interact with DNA along its major groove, forming stable UV-visible and CD-confirmed complexes, and upregulates key pancreatic differentiation transcription factors: PDX1 (1.6× increase), NGN3 (2.7×), PAX6 (1.8×), FOXA2, NKX2-2, NKX6.1, and PAX4—factors essential for islet cell maturation (https://www.corepeptides.com/pancragen-peptide-effects-on-cellular-metabolic-and-pancreatic-functions/). In rodent models of experimental diabetes mellitus, Pancragen normalized fasting glucose, reduced insulin resistance index, and normalized the dynamics of plasma insulin and C-peptide responses to glucose challenge, with effects persisting three weeks after cessation. The peptide also reduces proapoptotic p53 and increases antiapoptotic Mcl1 expression, alongside decreasing caspase-3 and cathepsin B activities in pancreatic cultures—protecting against diabetes-accelerated cell loss.
For Research Use Only. Not for human or veterinary use. Page copy reflects published preclinical and biochemistry literature only and does not constitute dosage, administration, treatment, or therapeutic guidance.
Catalog Context
Pancragen (KEDW) is supplied as a research-grade lyophilized peptide catalog item under the Peptide Bioregulators (Khavinson) family. PeptideDistro.com lists this entry for qualified research and wholesale buyers; pricing, MOQ, and documentation packets are reviewed during account intake. Page copy is framed exclusively around mechanism literature, molecular identifiers, and bulk catalog specifications.
Wholesale & Documentation
PeptideDistro.com supplies Pancragen (KEDW) in research-grade lyophilized format with COA, HPLC, and mass spectrometry data per lot. Pricing, MOQ, and label coordination are reviewed during account intake.